{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Collection&page=22", "query": { "intervention": "Serum Collection", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Collection&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Collection&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T02:16:49.206Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04941287", "title": "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Distal Bile Duct Adenocarcinoma", "Metastatic Gallbladder Carcinoma", "Metastatic Intrahepatic Cholangiocarcinoma", "Recurrent Distal Bile Duct Adenocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Liver Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Varlilumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2021-12-15", "completion_date": "2026-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04941287" }, { "nct_id": "NCT03793166", "title": "Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Lymph Nodes", "Metastatic Malignant Neoplasm in the Soft Tissue", "Metastatic Malignant Neoplasm in the Viscera", "Rhabdoid Tumor of the Kidney", "Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1175, "start_date": "2019-06-07", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 858, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03793166" }, { "nct_id": "NCT05977036", "title": "BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Breast Cancer", "Unresectable Breast Cancer" ], "interventions": [ { "name": "DiviTum® TKa assay", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2024-09-25", "completion_date": "2035-09-30", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05977036" }, { "nct_id": "NCT04058132", "title": "Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "Sildenafil Citrate 50Mg Tab", "type": "DRUG" }, { "name": "functional Near-infrared Spectroscopy (fNIRS)", "type": "DEVICE" }, { "name": "Carbon Dioxide (CO2) 5%", "type": "OTHER" }, { "name": "Neuropsychological Assessments", "type": "OTHER" }, { "name": "Gadolinium contrast infusion", "type": "DRUG" }, { "name": "Blood sample collection for research purposes", "type": "PROCEDURE" }, { "name": "Structural brain Magnetic Resonance Imaging (MRI", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER", "PROCEDURE" ], "sponsor": "Uniformed Services University of the Health Sciences", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1, "start_date": "2019-08-09", "completion_date": "2020-03-01", "has_results": false, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04058132" }, { "nct_id": "NCT07714421", "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "High Grade B-Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma", "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 20, "start_date": "2026-12-08", "completion_date": "2031-10-08", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07714421" }, { "nct_id": "NCT04836481", "title": "A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "Serum Sample Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2021-01-01", "completion_date": "2023-10-01", "has_results": false, "last_update_posted_date": "2024-02-29", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04836481" }, { "nct_id": "NCT03511365", "title": "Effects of Probiotic on Inflammation and Microbiota in Patients With NASH", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Alcoholic Fatty Liver Disease", "Probiotics MeSH Descriptor Data 2018", "Interleukin-17 MeSH Descriptor Data 2018" ], "interventions": [ { "name": "Probiotic Formulation VSL#3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-05-15", "completion_date": "2019-10-11", "has_results": false, "last_update_posted_date": "2020-01-07", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 1, "location_summary": "Manhasset, New York", "locations": [ { "city": "Manhasset", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511365" }, { "nct_id": "NCT03842228", "title": "Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2019-11-21", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 17, "location_summary": "Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more", "locations": [ { "city": "Buena Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03842228" }, { "nct_id": "NCT01875237", "title": "Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Myeloma", "Myeloproliferative Diseases" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Stem Cell infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mini Methotrexate", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion (DLI)", "type": "PROCEDURE" }, { "name": "AP1903", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 3, "start_date": "2013-12-27", "completion_date": "2017-03-07", "has_results": true, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01875237" }, { "nct_id": "NCT00444912", "title": "The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma", "Hodgkin Disease" ], "interventions": [ { "name": "G-CSF plus plerixafor", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2006-02", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2014-03-13", "last_synced_at": "2026-11-04T02:16:49.206Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00444912" } ] }